In recent years, autologous chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has risen as an important treatment option for relapsed/refractory (R/R) multiple myeloma (MM) [1, 2]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.